One-month immunotherapy trial in treatment-failed TB patients

作     者：Olga V. Arjanova Dmitry A. Butov Natalia D. Prihoda Svetlana I. Zaitzeva Larisa V. Yurchenko Nina I. Sokolenko Anna L. Stepanenko Tatyana S. Butova Elena A. Grinishina Olga A. Maksimenko Vichai Jirathitikal Aldar S. Bourinbaiar Valery M. Frolov Galyna A. Kutsyna 

作者机构：不详 

出 版 物：《Open Journal of Immunology》 (免疫学期刊（英文）)

年 卷 期：2011年第1卷第2期

页      面：50-55页

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：Biomarker HIV Inflammation MDR-TB Mycobacterium Survival Treatment Failure Vaccine 

摘      要：reatment failed TB patients have very limited chances of survival. Open label trial of daily oral pill of V-5 Immunitor (V5) was conducted in 48 treatment-failed TB patients on palliative support consisting of isoniazid (H) and rifampicin (R). The subjects had the following forms of TB;cavitary: disseminated: MDR-TB: DR-TB: TB/HIV at 35:13:7:4:1 ratio. After 1 month 62.5% of V5-treated patients experienced negative sputum smear conversion (P 2 respectively (P 0.0001). Two patients (4.2%) died from illicit drug- and alcohol-abuse related causes. No adverse effects or reactivation of disease due to immune intervention were seen at any time. V5 is safe and in combination with a simple two-drug regimen was highly effective as an immune adjunct to produce favorable outcome among treatment-failed and/ or drug-resistant TB patients.